Journal article
Medium-Term Bioresorbable Scaffold Outcomes Utilising Data From an Australian Clinical Quality Registry
LP Dawson, D Dinh, S Montalto, SJ Duffy, R Dick, J Gutman, A Brennan, H Carruthers, J Doyle, D Stub, R Whitbourn, N Cox, J Cooke, R Gooley, C Hiew, C Reid, J Lefkovits
Heart Lung and Circulation | ELSEVIER SCIENCE INC | Published : 2020
Abstract
Background: Bioresorbable scaffolds (BRS) are a novel technology in coronary intervention. However, recent trials demonstrate higher rates of device failure compared to contemporary drug-eluting stents. This study sought to utilise a clinical quality registry to assess the medium-term safety of the Abbott Absorb BRS (Abbott Vascular, Santa Clara, CA, USA), in an Australian context. Methods: A prospective, observational study of 192 BRS percutaneous coronary interventions (PCI) compared to 31,773 non-BRS PCIs entered in the Victorian Cardiac Outcomes Registry from 2013 to 2017. The main outcome measure was patient-oriented composite endpoint (POCE) events comprising all-cause mortality, any m..
View full abstractGrants
Funding Acknowledgements
The VCOR was initially funded by Medibank Private from 2011-2014 and the Victorian Department of Health and Human Services (DHHS). Ongoing funding has been provided from the DHHS and Victorian Cardiac Clinical Network.